Abstracts tagged "Disease-modifying antirheumatic drugs"

Abstract Number: 1843 • 2012 ACR/ARHP Annual Meeting
Predictors of Starting and Stopping Disease Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis: A 23 Year Longitudinal Cohort
Daniel H. Solomon¹, Edward H. Yelin², Jeffrey N. Katz³, Chris Tonner⁴, M. Alan Brookhart⁵, Seoyoung C. Kim⁶, Bing Lu⁷ and John Z. Ayanian⁸, ¹Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Medicine, UC San Francisco, San Francisco, CA, ³Rheumatology and Orthopedics, Brigham & Women's Hospital, Boston, MA, ⁴Medicine, UCSF, San Francisco, CA, ⁵University of North Carolina, Chapel Hill, NC, ⁶Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: DMARDs are the standard of care for rheumatoid arthritis (RA), however multiple studies find that not all patients use these agents. We examined predictors…
Abstract Number: 1844 • 2012 ACR/ARHP Annual Meeting
Inequities in Access to Biologic Disease-Modifying Anti-Rheumatic Drugs for Patients with Rheumatoid Arthritis Across 46 European Countries
Polina Putrik¹, Sofia Ramiro², Milena Pavlova³, Tore K. Kvien⁴, Tuulikki Sokka⁵, Till Uhlig⁴, Annelies Boonen⁶ and Equity In Access To Treatment of RA Across Europe⁷, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ³Health Services Research, Maastricht University, Maastricht, Netherlands, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁶Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁷European Region
Background/Purpose: In the treatment of patients with RA, EULAR recommends to initiate biologic DMARDs after failing synthetic DMARDs. However, biologics are costly, and it is…
Abstract Number: 1845 • 2012 ACR/ARHP Annual Meeting
Inequalities Across 46 European Countries in Clinical Eligibility Criteria for the Start of A First (Reimbursed) Biologic in Patients with Rheumatoid Arthritis
Polina Putrik¹, Sofia Ramiro², Tore K. Kvien³, Tuulikki Sokka⁴, Till Uhlig³, Annelies Boonen⁵ and Equity in Clinical Eligibility Criteria for RA treatment⁶, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁶European Region
Background/Purpose: In the treatment of patients with RA, strategies that include biologics have resulted in a better outcome for patients with regard to disease activity,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].